Switch from cyclosporine A to tacrolimus in renal transplant recipients: Impact on Th1, Th2, and monokine responses

Human Immunology

Volumn 61, Issue 9, 2000, Pages 884-897

  Weimer, Rolf ^a,b   Melk, Anette ^b   Daniel, Volker ^b   Friemann, Schirin ^a   Padberg, Winfried ^a   Opelz, Gerhard ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

CD4 help; CsA; Cytokines; Kidney transplantation; Tacrolimus

Indexed keywords

CD28 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CYCLOSPORIN A; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TSUKUBAENOLIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GINGIVA HYPERPLASIA; GRAFT REJECTION; HELPER CELL; HEMOLYTIC PLAQUE ASSAY; HIRSUTISM; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; HYPERLIPOPROTEINEMIA; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; KIDNEY TRANSPLANTATION; MONOCYTE; PRIORITY JOURNAL;

ANTIGENS, CD28; ANTIGENS, CD40; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; CELLS, CULTURED; CYCLOSPORINE; HUMAN; IMMUNOSUPPRESSIVE AGENTS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-1; INTERLEUKIN-6; KIDNEY TRANSPLANTATION; LIPOPOLYSACCHARIDES; MONOCYTES; MONOKINES; PHYTOHEMAGGLUTININS; RECEPTORS, INTERLEUKIN-2; RECEPTORS, INTERLEUKIN-6; RECEPTORS, TUMOR NECROSIS FACTOR; TACROLIMUS; TH1 CELLS; TH2 CELLS; TUMOR NECROSIS FACTOR;

EID: 0033783795     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(00)00152-X     Document Type: Article

References (82)

1. Chronic rejection in renal transplant recipients - Risk factors and correlates
2. Rethinking chronic allograft nephropathy: The concept of accelerated senescence
3. Chronic allograft nephropathy: An update
4. Chronic renal allograft rejection: Immunologic and nonimmunologic risk factors
5. The impact of an acute rejection episode on long-term renal allograft survival (t1/2)
6. Critical evaluation of the association of acute with chronic graft rejection in kidney and heart transplant recipients
7. Separate risk factors for the development of transplant glomerulopathy vs chronic tubulointerstitial rejection
8. The Canadian organ replacement register
9. Long-term results of solid organ transplantation: Report from the Eurotransplant International Foundation
10. A multi-factor analysis of kidney graft outcomes at one and five years posttransplantation: 1996 UNOS update
11. Tilney NL: Nephron mass modulates the hemodynamic, cellular, and molecular response of the rat renal allograft
12. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation
13. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection
14. Tacrolimus (FK 506) in kidney transplantation: Three-year survival results of the US multicenter, randomized, comparative trial
15. Pretransplant CD4 helper function and interleukin 10 response predict risk of acute kidney graft rejection
16. Superior 3-year kidney graft function in patients with impaired pretransplant Th2 responses
17. Increased T suppressor activity in renal transplant recipients with long-term stable graft function
18. IL-6 independent monocyte/B cell defect in renal transplant recipients with long-term stable graft function
19. Helper and suppressor T-cell function in HIV-infected hemophilia patients
20. Autoantibodies against CD4 cells are associated with CD4 helper defects in human immunodeficiency virus-infected patients
21. Association of viral load in plasma samples of HIV-infected hemophilia patients with autoantibodies and gp120-containing immune complexes on CD4+ lymphocytes
22. Analysis of the B7 costimulatory pathway in allograft rejection
23. A 39-kDa protein on activated helper T cells binds CD40 and trasnduces the signal for cognate activation of B cells
24. CD40 expression by human monocytes: Regulation by cytokines and activation of monocytes by the ligand for CD40
25. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2
26. CD28-B7 T cell costimulatory blockade by CTLA4Ig in the rat renal allograft model. Inhibition of cell-mediated and humoral immune responses in vivo
27. Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis
28. T-cell costimulatory blockade in exper imental chronic cardiac allograft rejection: Effects of cyclosporine and donor antigen
29. Adhesion molecule expression (ICAM-1, VCAM-1, Eselectin and PECAM) in human kidney allografts
30. Immunobiology of transplantation
31. Adhesion molecules and activation markers in acute rejection of human renal allografts
32. Expression of cell adhesion molecules in primary renal disease and renal allograft rejection
33. In vivo effects of monoclonal antibody to ICAM-1 (CD54) in non-human primates with renal allografts
34. Antibodies to ICAM-1 protect kidneys in severe ischemic reperfusion injury
35. Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury
36. Antisense oligonucleotides for ICAM-1 attenuate reperfusion injury and renal failure in the rat
37. Inhibition of accelerated coronary atherosclerosis with short-term blockade of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 in a heterotopic murine model of heart transplantation
38. A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (Enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: A report of the European Anti-ICAM-1 Renal Transplant Study Group
39. How cyclosporine modifies histological and molecular events in the vascular wall during chronic rejection of rat cardiac allografts
40. Risk factors for chronic rejection in renal allograft recipients
41. Effect of early cyclosporine levels on kidney allograft rejection
42. Relationship between maintenance dose of cyclosporine and long-term kidney graft survival
43. Impaired T-cell IL-10 secretion and CD4 helper function in liver transplant patients treated with tacrolimus
44. Cytokines, adhesion molecules, and the pathogenesis of chronic rejection of rat renal allografts
45. Monocyte activation for enhanced tumour necrosis factor-alpha and interleukin 6 production during chronic renal allograft rejection
46. Chronic rejection in experimental cardiac transplantation: Studies in the Lewis-F344 model
47. Sequential cytokine dynamics in chronic rejection of rat renal allografts: Roles for cytokines RANTES and MCP-1
48. Prevention of functional, structural, and molecular changes of chronic rejection of rat renal allografts by a specific macrophage inhibitor
49. Macrophages and chronic renal allograft nephropathy
50. Medial smooth muscle cell loss in arterial allografts occurs by cytolytic cell induced apoptosis
51. Macrophage migration inhibitory factor expression in human renal allograft rejection
52. The glutathione depleting agent diethylmaleate prolongs renal allograft survival
53. A dual mechanism of immunosuppression by FK-506. Differential suppression of IL-4 and IL-10 levels in T helper 2 cells
54. Heart allografts in murine systems: The differential activation of Th2-like effector cells in peripheral tolerance
55. Increased expression of IL-4 and IL-10 and decreased expression of IL-2 and interferon-γ in longsurviving mouse heart allografts after brief CD4-monoclonal antibody therapy
56. Lew-to-F344 carotid artery allografts. Analysis of a rat model of posttransplant vascular injury involving cell-mediated and humoral responses
57. Distinct tolerance pathways in sensitized allograft recipients after selective blockade of activation signal 1 or signal 2
58. Interleukin-10
59. Cytokines and natural regulators of cytokines
60. Dendritic cells as regulators of immune reactivity: Implications for transplantation
61. Interleukin 10 and transforming growth factor β cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A
62. IL-10 is a potent growth and differentiation factor for activated human B lymphocytes
63. IL-10 stimulates monocyte FcγR surface expression and cytotoxic activity
64. Systemic administration of cellular interleukin-10 can exacerbate cardiac allograft rejection in mice
65. Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation
66. High frequency of IL-10-secreting CD4+ graft-infiltrating T lymphocytes in promptly rejected kidney allografts
67. Predictive indicators of rejection or infection in renal transplant patients
68. Intragraft expression of IL-10 messenger RNA: A novel correlate of renal allograft rejection
69. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation
70. Clinical application of molecular biology: A study of allograft rejection with polymerase chain reaction
71. Cytokine analysis of human renal allograft aspiration biopsy cultures supernatants predicts acute rejection
72. Interleukin-10 and Epstein-Barr Virus induced post transplant lymphoproliferative disorder
73. ICAM-1, soluble-CD23, and interleukin-10 concentrations in serum in renal-transplant recipients with Epstein-Barr virus reactivation
74. Interleukin-10 and posttransplant lymphoproliferative disorder after kidney transplantation
75. Genotypic variation in the transforming growth factor-beta 1 gene: Association with transforming growth factor-beta 1 production, fibrotic lung disease, and graft fibrosis after lung transplantation
76. Differential effects of cyclosporin A and tacrolimus on the production of TGF-beta: Implications for the development of obliterative bronchiolitis after lung transplantation
77. Lipoprotein patterns in renal transplant patients: A comparison between FK 506 and cyclosporine A patients
78. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus
79. Effects of tacrolimus on hyperlipidemia after successful renal transplantation
80. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine
81. Immunosuppressive regimens and their effects on renal allograft outcome
82. Immunosuppression with FK 506 does not improve kidney graft survival. Collaborative Transplant Study